Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study

Table 2 Area under the curve (AUC) and thresholds for predicting SCAP in patients with CAP

	Threshold	Sensitivity (%)	Specificity (%)	AUC	p value	95% CI
	Threshold	Sensitivity (%)	Specificity (%)	AUC	p value	Lower limit	Higher limit
suPAR (ng/mL)	>4.33	76.70%	79.19%	0.835	<0.001	0.783	0.878
Syndecan-4 (ng/mL)	≤6.10	33.01%	81.88%	0.550	0.187	0.487	0.613
WBC (×10⁹/L)	>12.15	41.75%	79.19%	0.628	0.001	0.565	0.687
NLR	>5.61	76.24%	61.02%	0.725	<0.001	0.661	0.783
CRP (mg/L)	>90.48	56.32%	73.27%	0.642	0.001	0.569	0.710
PCT (μg/L)	>0.48	53.85%	75.44%	0.701	<0.001	0.620	0.773
CURB-65	>0	70.87%	68.35%	0.742	<0.001	0.682	0.796
PSI	>87	56.86%	92.03%	0.787	<0.001	0.729	0.837
APACHE II	>10	78.64%	82.55%	0.886	<0.001	0.840	0.923

SCAP severe community-acquired pneumonia, CAP community-acquired pneumonia, suPAR soluble urokinase-type plasminogen activator receptor, WBC whole blood leukocyte count, NLR neutrophil/lymphocyte ratio, CRP C-reactive protein, PCT procalcitonin, CURB-65 confusion, urea, respiratory rate, blood pressure, and age ≥65 years old score, PSI Pneumonia Severity Index score, APACHE II Acute Physiology and Chronic Health Evaluation II score

ISSN: 1364-8535